Key result
The doxorubicin analog MRA-CN was approximately 1000 times more potent against human carcinomas in vitro without an increase in cardiotoxicity compared to doxorubicin.
Why the study?
Does MRA-CN improve antitumor potency without increasing cardiotoxicity compared to doxorubicin in preclinical models?
Does MRA-CN improve antitumor potency without increasing cardiotoxicity compared to doxorubicin in preclinical models?
The doxorubicin analog MRA-CN dissociates antitumor efficacy from cardiotoxicity in preclinical models, offering a potentially safer anthracycline alternative.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for MRA-CN as a less cardiotoxic anthracycline; leaves open clinical translation of dissociated potency and cardiotoxicity.
The search for new congeners of the leading anticancer drug doxorubicin has led to an analog that is approximately 1000 times more potent, noncardiotoxic at therapeutic dose levels, and non-cross-resistant with doxorubicin. The new anthracycline, 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin (MRA-CN), is produced by incorporation of the 3' amino group of doxorubicin in a new cyanomorpholinyl ring. The marked increase in potency was observed against human ovarian and breast carcinomas in vitro; it was not accompanied by an increase in cardiotoxicity in fetal mouse heart cultures. Doxorubicin and MRA-CN both produced typical cardiac ultrastructural and biochemical changes, but at equimolar concentrations. In addition, MRA-CN was not cross-resistant with doxorubicin in a variant of the human sarcoma cell line MES-SA selected for resistance to doxorubicin. Thus antitumor efficacy was dissociated from both cardiotoxicity and cross-resistance by this modification of anthracycline structure.
No takes yet. Share an insight, caveat, or question.
Šikić et al. (1985) studied Human ovarian and breast carcinomas. 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin (MRA-CN) vs. Doxorubicin was evaluated on Antitumor potency and cardiotoxicity. The doxorubicin analog MRA-CN was approximately 1000 times more potent against human carcinomas in vitro without an increase in cardiotoxicity compared to doxorubicin.
Synapse has enriched 10 related papers. Consider them for comparative context: